Nvidia Weighs Expanding H200 AI Chip Production as China Demand Surges 
HSBC’s $13.6 Billion Take-Private Offer for Hang Seng Bank Gains Board Backing 
Rio Tinto Signs Interim Agreement With Yinhawangka Aboriginal Group Over Pilbara Mining Operations 
ANZ Faces Legal Battle as Former CEO Shayne Elliott Sues Over A$13.5 Million Bonus Dispute 
Trello Outage Disrupts Users as Access Issues Hit Atlassian’s Work Management Platform 
Intel’s Testing of China-Linked Chipmaking Tools Raises U.S. National Security Concerns 
Azul Airlines Wins Court Approval for $2 Billion Debt Restructuring and New Capital Raise 
SoftBank Shares Slide as Oracle’s AI Spending Plans Fuel Market Jitters 
Korea Zinc Plans $6.78 Billion U.S. Smelter Investment With Government Partnership 
Apple App Store Injunction Largely Upheld as Appeals Court Rules on Epic Games Case 
Strategy Retains Nasdaq 100 Spot Amid Growing Scrutiny of Bitcoin Treasury Model 
iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures 
SpaceX Begins IPO Preparations as Wall Street Banks Line Up for Advisory Roles 
Coca-Cola’s Costa Coffee Sale Faces Uncertainty as Talks With TDR Capital Hit Snag 
Coca-Cola’s Proposed Sale of Costa Coffee Faces Uncertainty Amid Price Dispute 
Fortescue Expands Copper Portfolio With Full Takeover of Alta Copper 
Air Force One Delivery Delayed to 2028 as Boeing Faces Rising Costs 
Eli Lilly and Company (NYSE: LLY) is reportedly in advanced talks to acquire gene editing biotech Verve Therapeutics Inc. (NASDAQ: VERV) in a deal valued at up to $1.3 billion, according to the Financial Times. This move underscores Eli Lilly’s aggressive expansion into genetic medicine as it seeks to boost its pipeline of experimental drugs.
Verve Therapeutics’ stock skyrocketed nearly 73% in after-hours trading, reaching $10.76, following the news. The proposed deal would include a $1 billion upfront payment and an additional $300 million tied to performance-based milestones. The acquisition price values Verve at approximately double its market capitalization of just over $500 million as of Monday's close.
The Boston-based Verve specializes in in vivo gene editing treatments aimed at cardiovascular disease. Eli Lilly’s interest lies in leveraging Verve’s proprietary CRISPR-based technology to diversify and enhance its R&D capabilities.
This potential acquisition adds to Eli Lilly’s recent M&A streak. Earlier in 2025, the pharmaceutical giant acquired Scorpion Therapeutics for $2.5 billion and SiteOne Therapeutics for $1 billion, signaling a clear strategy to invest in innovative biotech platforms.
Despite broader industry challenges, Eli Lilly continues to outperform competitors, driven by strong sales of its diabetes and weight-loss drugs Mounjaro and Zepbound. By acquiring Verve, Lilly aims to strengthen its long-term competitiveness in the fast-evolving field of gene therapies.
Investors are watching closely as the deal, if finalized, could mark a major turning point for both companies and the broader gene editing space. Eli Lilly’s push into advanced therapeutics reaffirms its leadership in shaping the future of precision medicine and biopharmaceutical innovation.
